title: A single institution experience with living donor liver transplantation for acute-on-chronic hepatitis B liver failure.
abstract: OBJECTIVE
  This study reports our preliminary experience of living donor liver transplantation (LDLT) for patients with acute-on-chronic liver failure (AoCLF) caused by hepatitis B.
  
  
  METHODS
  47 patients who demonstrated Ao- CLF caused by hepatitis B with mean (±SD) Model for End-Stage Liver Disease scores of 39.2±5.1 were divided by the transplantation group (n=19) and the non-transplantation group (n=28) according to whether or not undergoing LDLT. At the same time, 30 hepatitis B cirrhosis recipients who underwent LDLT and did not reach the criteria of AoCLF were selected as the control group (n=30). In the transplantation group, veno-venous bypass, molecular adsorbent recirculating system (MARS) and continuous renal replacement therapy (CRRT) were introduced. The intraoperative data, post-transplant complications and mortality were analyzed retrospectively.
  
  
  RESULTS
  There were no significant differences in survival rates of 1, 6 and 12 months and the postoperative complications except for pneumonia and diabetes, between the control group and the transplantation group (p>0.05). Recurrence of hepatitis B was not found in the recipients of the control group and the transplantation group.
  
  
  CONCLUSIONS
  Right-lobe LDLT may be an effective therapeutic option for patients with acute-on-chronic hepatitis B liver failure.
authors.affiliation: West China Medical School of Sichuan University, Chengdu, China.
authors.forename: Zheyu
authors.initials: Z
authors.lastname: Chen
authors.forename: Tianfu
authors.initials: T
authors.lastname: Wen
authors.forename: Yong
authors.initials: Y
authors.lastname: Zeng
authors.forename: Lichun
authors.initials: L
authors.lastname: Wang
authors.forename: Jia Jie
authors.initials: JJ
authors.lastname: Lu
authors.forename: Shu
authors.initials: S
authors.lastname: Gong
authors.forename: Hong
authors.initials: H
authors.lastname: Tan
authors.forename: Ping
authors.initials: P
authors.lastname: Feng
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Jichun
authors.initials: J
authors.lastname: Zhao
authors.forename: Wentao
authors.initials: W
authors.lastname: Wang
authors.forename: Mingqing
authors.initials: M
authors.lastname: Xu
authors.forename: Jiayin
authors.initials: J
authors.lastname: Yang
authors.forename: Hong
authors.initials: H
authors.lastname: Wu
authors.forename: Lunan
authors.initials: L
authors.lastname: Yan
mesh_terms: D000328:Adult; D058625:End Stage Liver Disease / Q000601:surgery*; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D007165:Immunosuppression Therapy; D017114:Liver Failure, Acute / Q000601:surgery*; D016031:Liver Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged
chemical_list: D007136:Immunoglobulins; C045213:hepatitis B hyperimmune globulin